Read this company snapshot
Daily valuation snapshot
Oragenics Inc.: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.46
- Market capitalization (USD)
- $2,057,452.39
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.56
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OGEN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OGEN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Products. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing OGEN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $0.46 |
| Market capitalization (USD) | $2,057,452.39 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.56 |
No matching rows. Clear the filter to see all records.
Read OGEN's valuation metrics
Company size
Oragenics Inc.'s recorded market capitalization is $2,057,452.39. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
OGEN's recorded price-to-book ratio is 0.56. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Oragenics Inc. with Aurora
Use the snapshot above to ask a specific question about OGEN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow OGEN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.